Bausch Health Companies Inc. (TSE:BHC - Free Report) - Equities research analysts at Zacks Research reduced their Q2 2025 earnings estimates for shares of Bausch Health Companies in a research report issued on Monday, June 23rd. Zacks Research analyst R. Department now forecasts that the company will earn $1.36 per share for the quarter, down from their prior forecast of $1.37. The consensus estimate for Bausch Health Companies' current full-year earnings is $5.55 per share. Zacks Research also issued estimates for Bausch Health Companies' Q3 2025 earnings at $1.46 EPS, FY2025 earnings at $5.27 EPS, Q1 2026 earnings at $1.21 EPS, Q2 2026 earnings at $1.35 EPS, Q3 2026 earnings at $1.57 EPS, Q4 2026 earnings at $1.54 EPS, FY2026 earnings at $5.67 EPS, Q1 2027 earnings at $1.51 EPS and FY2027 earnings at $6.71 EPS.
Bausch Health Companies Stock Performance
Shares of TSE:BHC traded up C$0.09 on Thursday, reaching C$8.83. 672,617 shares of the company's stock were exchanged, compared to its average volume of 366,877. The company has a fifty day moving average of C$7.08 and a 200-day moving average of C$8.89. Bausch Health Companies has a twelve month low of C$5.45 and a twelve month high of C$13.74. The company has a market capitalization of C$2.30 billion, a price-to-earnings ratio of -12.92, a PEG ratio of 0.21 and a beta of 0.77. The company has a current ratio of 1.19, a quick ratio of 0.58 and a debt-to-equity ratio of -1,831.94.
Insiders Place Their Bets
In other news, Director John Paulson purchased 754,134 shares of Bausch Health Companies stock in a transaction that occurred on Tuesday, June 10th. The shares were acquired at an average price of C$6.87 per share, for a total transaction of C$5,179,392.31. Insiders have acquired a total of 3,553,401 shares of company stock worth $27,087,675 in the last quarter. Corporate insiders own 11.28% of the company's stock.
About Bausch Health Companies
(
Get Free Report)
Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.
Further Reading
Before you consider Bausch Health Companies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bausch Health Companies wasn't on the list.
While Bausch Health Companies currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
